Eli Lilly | LLY - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
AbbVie USD 3.58B 316M 2026-03
Abbott USD 3.27B 138M 2026-03
ALKERMES USD 264.59M 77.4M 2026-03
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Baxter International USD 728M 33M 2026-03
Biogen USD 554.3M 128.2M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Drreddys Laboratories INR 26.92B 3.74B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
J&J USD 6.03B 719M 2026-03
Medtronic 2.96B 9M 2025-12
Merck USD 2.67B 180M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03
Novartis USD 3.44B 132M 2025-12
Novo Nordisk DKK 13.22B 4.22B 2026-03
Perrigo USD 267.3M 11.4M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 30.28M 606K 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.33B 419M 2026-03
Sanofi EUR 2.75B 455M 2025-12
United Therapeutics USD 156.6M 34M 2026-03
Zoetis USD 588M 31M 2026-03